Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial.

Wermke M, Eckoldt J, Götze KS, Klein SA, Bug G, de Wreede LC, Kramer M, Stölzel F, von Bonin M, Schetelig J, Laniado M, Plodeck V, Hofmann WK, Ehninger G, Bornhäuser M, Wolf D, Theurl I, Platzbecker U.

Lancet Haematol. 2018 Apr 5. pii: S2352-3026(18)30036-X. doi: 10.1016/S2352-3026(18)30036-X. [Epub ahead of print]

PMID:
29628397
2.

Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.

Pishali Bejestani E, Cartellieri M, Bergmann R, Ehninger A, Loff S, Kramer M, Spehr J, Dietrich A, Feldmann A, Albert S, Wermke M, Baumann M, Krause M, Bornhäuser M, Ehninger G, Bachmann M, von Bonin M.

Oncoimmunology. 2017 Jun 20;6(10):e1342909. doi: 10.1080/2162402X.2017.1342909. eCollection 2017.

PMID:
29123951
3.

Myocardial ischemia detection with single-phase CT perfusion in symptomatic patients using high-pitch helical image acquisition technique.

Bischoff B, Deseive S, Rampp M, Todica A, Wermke M, Martinoff S, Massberg S, Reiser MF, Becker HC, Hausleiter J.

Int J Cardiovasc Imaging. 2017 Apr;33(4):569-576. doi: 10.1007/s10554-016-1020-z. Epub 2016 Nov 15.

PMID:
27848163
4.

Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).

Wermke M, Schuster C, Nolte F, Al-Ali HK, Kiewe P, Schönefeldt C, Jakob C, von Bonin M, Hentschel L, Klut IM, Ehninger G, Bornhäuser M, Baretton G, Germing U, Herbst R, Haase D, Hofmann WK, Platzbecker U.

Br J Haematol. 2016 Dec;175(5):917-924. doi: 10.1111/bjh.14345. Epub 2016 Oct 7.

PMID:
27714772
5.

Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.

Balaian E, Schuster C, Schönefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhäuser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M.

Ann Hematol. 2016 Oct;95(11):1805-10. doi: 10.1007/s00277-016-2775-y. Epub 2016 Aug 10.

PMID:
27510179
6.

Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.

von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, Stölzel F, Parmentier S, Sockel K, Krech M, Schmitz M, Platzbecker U, Schetelig J, Bornhäuser M, von Bonin M.

Stem Cells. 2016 Feb;34(2):357-66. doi: 10.1002/stem.2224. Epub 2015 Oct 13.

7.

Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?

Wermke M, Gloaguen S, Platzbecker U.

Curr Hematol Malig Rep. 2015 Sep;10(3):329-33. doi: 10.1007/s11899-015-0276-z. Review.

PMID:
26126601
8.

RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug.

Wermke M, Camgoz A, Paszkowski-Rogacz M, Thieme S, von Bonin M, Dahl A, Platzbecker U, Theis M, Ehninger G, Brenner S, Bornhäuser M, Buchholz F.

Blood. 2015 Jun 11;125(24):3760-8. doi: 10.1182/blood-2014-07-590646. Epub 2015 Apr 30.

9.

A rare case for gas in the heart: diagnosis and treatment.

Pannach S, Weise M, Wermke M.

Eur Heart J Cardiovasc Imaging. 2015 Jun;16(6):693. doi: 10.1093/ehjci/jev036. Epub 2015 Feb 25. No abstract available.

PMID:
25719179
10.

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G.

J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Epub 2014 Dec 29. Erratum in: J Clin Oncol. 2015 May 1;33(13):1519.

PMID:
25547501
11.

Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia.

Platzbecker U, Sockel K, Schönefeldt C, Nowak D, Helas S, Röllig C, Mossner M, Jann JC, Ehninger G, Hofmann WK, Bornhäuser M, Thiede C, Wermke M.

Haematologica. 2014 Dec;99(12):e247-8. doi: 10.3324/haematol.2014.111948. Epub 2014 Sep 5. No abstract available.

12.

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.

Ehninger A, Kramer M, Röllig C, Thiede C, Bornhäuser M, von Bonin M, Wermke M, Feldmann A, Bachmann M, Ehninger G, Oelschlägel U.

Blood Cancer J. 2014 Jun 13;4:e218. doi: 10.1038/bcj.2014.39.

13.

Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis.

Armand P, Kim HT, Virtanen JM, Parkkola RK, Itälä-Remes MA, Majhail NS, Burns LJ, DeFor T, Trottier B, Platzbecker U, Antin JH, Wermke M.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1248-51. doi: 10.1016/j.bbmt.2014.04.024. Epub 2014 Apr 24.

14.

Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome.

Stölzel F, Kramer M, Mohr B, Wermke M, Bornhäuser M, Ehninger G, Schaich M, Platzbecker U.

Leukemia. 2014 Mar;28(3):723-5. doi: 10.1038/leu.2013.356. Epub 2013 Nov 25. No abstract available.

PMID:
24270741
15.

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.

Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A.

Leukemia. 2014 Mar;28(3):696-8. doi: 10.1038/leu.2013.325. Epub 2013 Nov 4. No abstract available.

PMID:
24186004
16.

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation.

Schönefeldt C, Sockel K, Wehner R, Sopper S, Wolf D, Wermke M, Thiede C, Oelschlägel U, Ehninger G, Bornhäuser M, Platzbecker U, Schmitz M.

Blood Cancer J. 2013 Aug 30;3:e136. doi: 10.1038/bcj.2013.35. No abstract available.

17.

Comparing propofol versus sevoflurane anesthesia for epileptogenic focus detection during positron emission tomography in pediatric patients.

Wagner KJ, Schulz CM, Sprenger T, Pieper T, Heuser F, Hohmann CP, Wermke M, Martin J, Drzezga A.

Minerva Anestesiol. 2013 Nov;79(11):1264-8. Epub 2013 Jul 1.

PMID:
23811627
18.

In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice.

von Bonin M, Wermke M, Cosgun KN, Thiede C, Bornhauser M, Wagemaker G, Waskow C.

PLoS One. 2013 Apr 9;8(4):e60680. doi: 10.1371/journal.pone.0060680. Print 2013.

19.

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.

Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönefeldt C, Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann WK, Ehninger G, Germing U, Haase D, Wermke M.

Leukemia. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28. No abstract available.

20.

Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantation.

Bahr F, Wehner R, Platzbecker U, Wermke M, Shayegi N, Middeke JM, Röllig C, Schetelig J, Ehninger G, Schmitz M, Bornhäuser M, Tuve S.

Biol Blood Marrow Transplant. 2013 Mar;19(3):357-65. doi: 10.1016/j.bbmt.2012.11.018. Epub 2012 Nov 30.

21.

MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.

Wermke M, Schmidt A, Middeke JM, Sockel K, von Bonin M, Schönefeldt C, Mair S, Plodeck V, Laniado M, Weiss G, Schetelig J, Ehninger G, Theurl I, Bornhäuser M, Platzbecker U.

Clin Cancer Res. 2012 Dec 1;18(23):6460-8. doi: 10.1158/1078-0432.CCR-12-1683. Epub 2012 Sep 18.

22.

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.

Sockel K, Bornhaeuser M, Mischak-Weissinger E, Trenschel R, Wermke M, Unzicker C, Kobbe G, Finke J, Germing U, Mohr B, Greiner J, Beelen D, Thiede C, Ehninger G, Platzbecker U; German MDS and Cooperative Transplant Study Group (GCTSG).

Haematologica. 2012 Sep;97(9):e34-5. No abstract available.

23.

Reconstitution of 6-sulfo LacNAc dendritic cells after allogeneic stem-cell transplantation.

Mager K, Wehner R, Bahr F, Oelschlägel U, Platzbecker U, Wermke M, Shayegi N, Middeke JM, Radke J, Röllig C, Schetelig J, Thiede C, Ehninger G, Schmitz M, Bornhäuser M, Tuve S.

Transplantation. 2012 Jun 27;93(12):1270-5. doi: 10.1097/TP.0b013e31824fd8b4.

PMID:
22643330
24.

Respiratory failure in patients undergoing allogeneic hematopoietic SCT--a randomized trial on early non-invasive ventilation based on standard care hematology wards.

Wermke M, Schiemanck S, Höffken G, Ehninger G, Bornhäuser M, Illmer T.

Bone Marrow Transplant. 2012 Apr;47(4):574-80. doi: 10.1038/bmt.2011.160. Epub 2011 Sep 19.

PMID:
21927036
25.

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M, Thiede C.

Leukemia. 2012 Mar;26(3):381-9. doi: 10.1038/leu.2011.234. Epub 2011 Sep 2.

26.

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.

Sockel K, Wermke M, Radke J, Kiani A, Schaich M, Bornhäuser M, Ehninger G, Thiede C, Platzbecker U.

Haematologica. 2011 Oct;96(10):1568-70. doi: 10.3324/haematol.2011.044388. Epub 2011 Jul 12. No abstract available.

27.

Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.

Bornhäuser M, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J, Lehmann D, Hölig K, Radke J, Tuve S, Wermke M, Wehner R, Jähnisch H, Bachmann MP, Rieber EP, Schetelig J, Ehninger G, Schmitz M.

Blood. 2011 Jun 30;117(26):7174-84. doi: 10.1182/blood-2010-09-308569. Epub 2011 May 3.

28.

Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy.

Tuve S, Gayoso J, Scheid C, Radke J, Kiani A, Serrano D, Platzbecker U, Rodríguez-Macías G, Wermke M, Holtick U, Balsalobre P, Middeke JM, Shayegi N, Chemnitz JM, Krause A, Gruner N, Füssel M, Schetelig J, Thiede C, Ehninger G, Hallek M, Díez-Martín JL, Bornhäuser M.

Leukemia. 2011 May;25(5):880-3. doi: 10.1038/leu.2011.11. Epub 2011 Feb 11. No abstract available.

PMID:
21311556
29.

Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation.

Wermke M, Maiwald S, Schmelz R, Thiede C, Schetelig J, Ehninger G, Bornhäuser M, Wassmuth R.

Biol Blood Marrow Transplant. 2010 Dec;16(12):1718-27. doi: 10.1016/j.bbmt.2010.06.001. Epub 2010 Jun 9.

30.

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.

Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, Platzbecker U, Stuhlmann R, Schuler U, Soucek S, Kramer M, Mohr B, Oelschlaegel U, Stölzel F, von Bonin M, Wermke M, Wandt H, Ehninger G, Schaich M; Study Alliance Leukemia.

Blood. 2010 Aug 12;116(6):971-8. doi: 10.1182/blood-2010-01-267302. Epub 2010 May 4.

31.

188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.

Lauter A, Strumpf A, Platzbecker U, Schetelig J, Wermke M, Radke J, Kiani A, Wunderlich G, Thiede C, Ehninger G, Kotzerke J, Bornhäuser M.

Br J Haematol. 2010 Mar;148(6):910-7. doi: 10.1111/j.1365-2141.2009.08025.x. Epub 2009 Dec 7.

PMID:
19995390
32.

Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab.

Wermke M, von Bonin M, Gehrisch S, Siegert G, Ehninger G, Platzbecker U.

Haematologica. 2010 Mar;95(3):521-2. doi: 10.3324/haematol.2009.017749. Epub 2009 Nov 10. No abstract available.

33.

Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide.

Stölzel F, Wermke M, Röllig C, Thiede C, Platzbecker U, Bornhäuser M.

Haematologica. 2010 Jan;95(1):171-2. doi: 10.3324/haematol.2009.016568. Epub 2009 Oct 8. No abstract available.

34.

Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine.

Wermke M, Thiede C, Kiani A, Ehninger G, Bornhäuser M, Platzbecker U.

Leukemia. 2010 Jan;24(1):236-7. doi: 10.1038/leu.2009.204. Epub 2009 Sep 24. No abstract available.

PMID:
19776758
35.

A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer's disease.

Wermke M, Sorg C, Wohlschläger AM, Drzezga A.

Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S12-24. doi: 10.1007/s00259-007-0698-5. Review.

PMID:
18299829
36.

Frontal diaschisis in a German case of fatal familial insomnia.

Wermke M, Teipel S, Fuchsberger T, Kretzschmar H, Westner I, Schröder M, Hampel H, Drzezga A.

J Neurol. 2006 Nov;253(11):1510-2. Epub 2006 Oct 13. No abstract available.

PMID:
17041739
37.

Impaired cross-modal inhibition in Alzheimer disease.

Drzezga A, Grimmer T, Peller M, Wermke M, Siebner H, Rauschecker JP, Schwaiger M, Kurz A.

PLoS Med. 2005 Oct;2(10):e288. Epub 2005 Sep 20.

38.

Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.

Steudel C, Wermke M, Schaich M, Schäkel U, Illmer T, Ehninger G, Thiede C.

Genes Chromosomes Cancer. 2003 Jul;37(3):237-51.

PMID:
12759922
39.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T.

Blood. 2002 Jun 15;99(12):4326-35.

40.

[Videodensitometry of the ultrasonic tomogram for tissue differentiation of the liver (author's transl)].

Raab K, Schilling H, Wermke M, Wünsche A.

Radiol Diagn (Berl). 1982;23(2):127-34. German. No abstract available.

PMID:
7100432

Supplemental Content

Loading ...
Support Center